MedTrace Logo

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

NCT05350163 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-12-10

Study results available
· View outcomes & findings →

Summary

This pilot study is being conducted to treat patients who have a certain type of malignancy (lymphoid or myeloid) with immune effector cells after a T-cell depleted allogeneic hematopoietic cell transplantation (TCD HSCT).

This study is designed to see whether an investigational cellular product of immune cells obtained from a donor's cells that have been treated so that the type of cells that can lead to graft vs host disease have been removed can be safely administered. These cell products are administered following the initial stem cell transplant to assess the effect and improvement on minimal residual disease status, infectious complication, progression-free and overall survival.

Conditions

  • Lymphoid Leukemia, Acute
  • Myeloid Malignancy
  • Plasma Cell Tumor

Interventions

BIOLOGICAL

T-cell Receptor α/β Depleted Donor Lymphocyte Infusions

T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients

Sponsors & Collaborators

  • Guenther Koehne

    lead OTHER

Principal Investigators

  • Guenther Koehne, MD, PhD · Miami Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-05
Primary Completion
2023-09-18
Completion
2023-09-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05350163 on ClinicalTrials.gov